Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | TP53 wild-type |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
TP53 wild-type | ovarian cancer | no benefit | p53-SLP vaccine | Phase II | Actionable | In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579). | 21328579 19621448 | |
TP53 wild-type | ovarian cancer | predicted - sensitive | Ad.p53-DC vaccine | Phase I | Actionable | In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456). | 15297186 21927947 19621448 12082455 12082456 | |
TP53 wild-type | Advanced Solid Tumor | decreased response | Pazopanib + Vorinostat | Phase I | Actionable | In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)). | detail... | |
TP53 wild-type | liposarcoma | predicted - sensitive | MK-8242 | Phase I | Actionable | In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971). | 28240971 | |
TP53 wild-type | Advanced Solid Tumor | unknown | MK-8242 | Phase I | Actionable | In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971). | 28240971 | |
TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | ALRN-6924 | Phase I | Actionable | In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 59% (24/41), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 20 patients demonstrating stable disease (PMID: 34301750; NCT02264613). | 34301750 | |
TP53 wild-type | lymphoma | predicted - sensitive | ALRN-6924 | Phase I | Actionable | In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 59% (24/41), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 20 patients demonstrating stable disease (PMID: 34301750; NCT02264613). | 34301750 | |
TP53 wild-type | Advanced Solid Tumor | sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 80% (31/39) of patients with TP53 wild-type advanced solid tumors, with a median duration of 3.1 months (PMID: 31359240; NCT01723020). | 31359240 | |
TP53 wild-type | liposarcoma | predicted - sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 100% (10/10) of patients with TP53 wild-type well-differentiated liposarcomas (WDLPS) and 70% (7/10) of patients with TP53 wild-type de-differentiated liposarcomas, with median duration of 3.9 and 2.0 months respectively, and one patient with WDLPS achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020). | 31359240 | |
TP53 wild-type | estrogen-receptor positive breast cancer | predicted - sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 83.3% (10/12) of patients with TP53 wild-type ER-positive breast cancer (BC), with a median duration of 2.0 months in ER-positive, PR-positive BC, 1.4 months in ER-positive, PR-negative BC, and one patient achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020). | 31359240 | |
TP53 wild-type | multiple myeloma | predicted - sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 50% (5/10) of patients with TP53 wild-type multiple myeloma (PMID: 31359240; NCT01723020). | 31359240 | |
TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | BI 907828 + Ezabenlimab | Phase I | Actionable | In a Phase I trial, Ezabenlimab (BI 754091) and BI 907828 combination therapy demonstrated safety in patients with TP53 wild-type advanced solid tumors (n=9), and resulted in a partial response (PR) in 2 patients with biliary tract carcinoma, 1 urothelial carcinoma patient, and 1 myxoid liposarcoma patient, an unconfirmed PR in an intrahepatic cholangiocarcinoma patient, and stable disease in 4 patients with liposarcoma or gastric cancer (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3095; NCT03964233). | detail... | |
TP53 wild-type | acute myeloid leukemia | predicted - sensitive | Siremadlin | Phase I | Actionable | In a Phase I trial, Siremadlin (HDM201) treatment demonstrated safety and resulted in overall response rates of 4.2% (1/24), 20% (3/15), and 22.2% (6/27) for the recommended expansion doses of 120 mg, 250 mg, and 45 mg, respectively, in patients with TP53 wild-type acute myeloid leukemia (PMID: 34862243; NCT02143635). | 34862243 | |
TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | Siremadlin | Phase I | Actionable | In a Phase I trial, Siremadlin (HDM201) treatment demonstrated safety and resulted in an overall response rate (ORR) of 3.5% (4/115; all partial responses) and disease control rate (DCR) of 36.5% in patients with TP53 wild-type advanced solid tumors, and at the recommended dose for expansion (120 mg), resulted in an ORR of 10.5% (3/29) and DCR of 44.8% in all patients, and a DCR of 83.3% (10/12) in patients with liposarcoma (PMID: 34862243; NCT02143635). | 34862243 | |
TP53 wild-type | peripheral T-cell lymphoma | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (PMID: 34301750; NCT02264613). | 34301750 | |
TP53 wild-type | Merkel cell carcinoma | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (PMID: 34301750; NCT02264613). | 34301750 | |
TP53 wild-type | colorectal cancer | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (PMID: 34301750; NCT02264613). | 34301750 | |
TP53 wild-type | liposarcoma | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (PMID: 34301750; NCT02264613). | 34301750 | |
TP53 wild-type | breast cancer | predicted - sensitive | SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850). | 27765850 | |
TP53 wild-type | salivary gland adenoid cystic carcinoma | predicted - sensitive | SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with SAR405838 (MI-773) resulted in activation of Mdm2 and Tp53 in patient-derived salivary gland adenoid cystic carcinoma (ACC) cells in culture, and led to induction of apoptosis and tumor regression in ACC patient-derived xenograft (PDX) models with wild-type TP53 (PMID: 26936915). | 26936915 | |
TP53 wild-type | salivary gland adenoid cystic carcinoma | predicted - sensitive | Cisplatin + SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999). | 27550999 | |
TP53 wild-type | sarcoma | sensitive | Adavosertib + Gemcitabine | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, the combination of Adavosertib (MK-1775) and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471). | 23520471 | |
TP53 wild-type | colorectal cancer | predicted - sensitive | Mirdametinib + Sapanisertib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Sapanisertib (MLN0128) and Gomekli (mirdametinib) synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063). | 26272063 | |
TP53 wild-type | acute leukemia | sensitive | SAR405838 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672). | 25145672 | |
TP53 wild-type | prostate cancer | sensitive | SAR405838 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672). | 25145672 | |
TP53 wild-type | colon cancer | sensitive | SAR405838 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672). | 25145672 | |
TP53 wild-type | Advanced Solid Tumor | sensitive | KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130). | 25567130 | |
TP53 wild-type | lung non-small cell carcinoma | sensitive | KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130). | 25567130 | |
TP53 wild-type | lung non-small cell carcinoma | sensitive | Cisplatin + KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of KRT-232 (AMG 232) and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130). | 25567130 | |
TP53 wild-type | lung non-small cell carcinoma | sensitive | Carboplatin + KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of KRT-232 (AMG 232) and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130). | 25567130 | |
TP53 wild-type | lung cancer | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687). | 26162687 | |
TP53 wild-type | melanoma | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687). | 26162687 | |
TP53 wild-type | breast cancer | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687). | 26162687 | |
TP53 wild-type | colon cancer | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687). | 26162687 | |
TP53 wild-type | osteosarcoma | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687). | 26162687 | |
TP53 wild-type | fibrosarcoma | sensitive | Pegylated liposomal doxorubicin + RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... | |
TP53 wild-type | acute myeloid leukemia | sensitive | RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... | |
TP53 wild-type | acute myeloid leukemia | sensitive | Cytarabine + RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... | |
TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | Siremadlin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855). | detail... | |
TP53 wild-type | melanoma | sensitive | APR-246 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882). | 21239882 | |
TP53 wild-type | lung large cell carcinoma | resistant | NSC319726 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712). | 22624712 | |
TP53 wild-type | endometrioid ovary carcinoma | sensitive | thioureidobutyronitrile | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221). | detail... | |
TP53 wild-type | papillary thyroid carcinoma | sensitive | Alrizomadlin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with Alrizomadlin (APG-115) demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808). | 28498808 | |
TP53 wild-type | meningioma | sensitive | CEP1347 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-1347 induced apoptosis, inhibited viability, and decreased colony formation in a TP53 wild-type meningioma cell line in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37509605). | 37509605 | |
TP53 wild-type | acute myeloid leukemia | sensitive | ALRN-6924 | Preclinical - Patient cell culture | Actionable | In a preclinical study, ALRN-6924 inhibited growth of cells derived from patients with TP53 wild-type acute myeloid leukemia in culture, and inhibited leukemia cell growth, prolonged survival in cell line xenograft models (PMID: 29643228). | 29643228 | |
TP53 wild-type | colon cancer | sensitive | Trifluridine | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705). | 25700705 | |
TP53 wild-type | lung cancer | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687). | 26162687 | |
TP53 wild-type | breast cancer | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) activated Tp53 signaling, resulting in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687). | 26162687 | |
TP53 wild-type | colon cancer | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687). | 26162687 | |
TP53 wild-type | melanoma | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687). | 26162687 | |
TP53 wild-type | osteosarcoma | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687). | 26162687 | |
TP53 wild-type | lung carcinoma | sensitive | Ceralasertib + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). | 28062704 | |
TP53 wild-type | colorectal cancer | predicted - sensitive | MK-8745 | Preclinical - Cell culture | Actionable | In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494). | 22293494 | |
TP53 wild-type | lung non-small cell carcinoma | sensitive | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161). | 22862161 | |
TP53 wild-type | gastric adenocarcinoma | no benefit | Adavosertib + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, Adavosertib (MK-1775) treatment did not sensitize TP53 wild-type gastric adenocarcinoma cells to radiation therapy in culture (PMID: 32220892). | 32220892 | |
TP53 wild-type | high grade glioma | predicted - sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 wild-type malignant glioma cell lines in culture, however, the effect was smaller compared to the effects in TP53 mutant cell lines (PMID: 29769307). | 29769307 | |
TP53 wild-type | colon carcinoma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 wild-type colon carcinoma cells compared to radiotherapy alone in culture, and wild-type TP53 cells were more sensitive to the treatment combination than TP53 mutant cells (PMID: 29769307). | 29769307 | |
TP53 wild-type | liposarcoma | sensitive | BI 907828 | Preclinical - Cell culture | Actionable | In a preclinical study, BI 907828 inhibited viability of TP53 wild-type liposarcoma cell lines in culture (PMID: 39259562). | 39259562 | |
TP53 wild-type | renal cell carcinoma | sensitive | BI 907828 | Preclinical - Cell culture | Actionable | In a preclinical study, BI 907828 inhibited viability of TP53 wild-type renal cell carcinoma cell lines in culture (PMID: 39259562). | 39259562 | |
TP53 wild-type | melanoma | sensitive | BI 907828 | Preclinical - Cell culture | Actionable | In a preclinical study, BI 907828 inhibited viability of TP53 wild-type melanoma cell lines in culture (PMID: 39259562). | 39259562 | |
TP53 wild-type | colon cancer | sensitive | Adavosertib + PF-00477736 | Preclinical | Actionable | In a preclinical study, Adavosertib (MK-1775), in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237). | 22713237 | |
TP53 wild-type | medulloblastoma | sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268). | 24231268 | |
TP53 wild-type | colon carcinoma | sensitive | MPI-0479605 | Preclinical | Actionable | In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130). | 21980130 | |
TP53 wild-type | lung non-small cell carcinoma | sensitive | CEP-8983 + Cisplatin | Preclinical | Actionable | In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903). | 23428903 | |
TP53 wild-type | colon cancer | sensitive | CPUY201112 | Preclinical | Actionable | In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233). | 26743233 | |
TP53 wild-type | osteosarcoma | sensitive | CPUY201112 | Preclinical | Actionable | In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233). | 26743233 | |
TP53 wild-type | neuroblastoma | predicted - sensitive | GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463). | 25658463 | |
TP53 wild-type | neuroblastoma | predicted - sensitive | Carboplatin + GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463). | 25658463 | |
TP53 wild-type | neuroblastoma | predicted - sensitive | Doxorubicin + GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463). | 25658463 | |
TP53 wild-type | Advanced Solid Tumor | sensitive | CTX-1 | Preclinical | Actionable | In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273). | 26883273 | |
TP53 wild-type | acute myeloid leukemia | sensitive | CTX-1 | Preclinical | Actionable | In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273). | 26883273 | |
TP53 wild-type | acute myeloid leukemia | sensitive | CTX-1 + Nutlin-3a | Preclinical | Actionable | In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273). | 26883273 | |
TP53 wild-type | Advanced Solid Tumor | sensitive | CTX-1 + Nutlin-3a | Preclinical | Actionable | In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273). | 26883273 | |
TP53 wild-type | colorectal cancer | sensitive | Prodigiosin | Preclinical | Actionable | In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239). | 26759239 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: